

JOHNSON WINTER & SLATTERY
LAWYERS

Partner: Tim Bowley +61 2 8274 9574
Email: tim.bowley@jws.com.au
Associate: Tim Kennedy +61 2 8274 9523
Email: tim.kennedy@jws.com.au
Our Ref: A5792

2 May 2011

Company Announcements Platform
ASX Limited
Level 4, 20 Bridge Street
SYDNEY NSW 2000
By facsimile 1300 135 638

ChemGenex Pharmaceuticals Ltd
Level 4, 199 Moorabool Street
GEELONG VIC 3220
By facsimile (03) 5229 0100 and post

5 PAGES

Dear Sir / Madam

Cephalon CXS Holdings Pty Ltd ("Cephalon CXS") – Notice of change of interests of substantial holder in relation to shares in ChemGenex Pharmaceuticals Ltd ("ChemGenex")

We act for Cephalon CXS, a wholly owned subsidiary of Cephalon, Inc., in relation to the off-market takeover bid by Cephalon CXS for ChemGenex comprising an offer for all of the ordinary shares in ChemGenex (**ChemGenex Shares**) and an offer for all of the ASX-listed options in ChemGenex (**ChemGenex Listed Options**).

In accordance with section 671B(1)(b) of the Corporations Act 2001 (Cth) (**Corporations Act**), we attach an ASIC Form 604 (Notice of change of interests of substantial holder) (**ASIC Form**) issued by Cephalon CXS in relation to ChemGenex Shares.

As of 29 April 2011, no acceptance instructions were held under the Institutional Acceptance Facility (the terms of which are described in the supplementary bidder's statement dated and lodged with ASIC on 29 April 2011).

We also inform you that Cephalon CXS has at the date of this letter received acceptances in respect of 6,157,740 ChemGenex Listed Options, representing in aggregate 56.24% of all issued ChemGenex Listed Options (calculated on the basis of there being 10,949,328 ChemGenex Listed Options, as disclosed in ChemGenex's most recent Appendix 3B of 29 April 2011).

This letter and the attached ASIC Form will be sent by facsimile and post to ChemGenex today.

Yours faithfully



Australia Square
Level 30, 264 George Street
SYDNEY NSW 2000

T +61 2 8274 9555 | F +61 2 8274 9500

www.jws.com.au

SYDNEY | PERTH | MELBOURNE | BRISBANE | ADELAIDE

Liability limited by a scheme approved under Professional Standards Legislation

Form 604
Corporations Act 2001
Section 671B

Notice of change of interests of substantial holder

To Company Name/Scheme: ChemGenex Pharmaceuticals Ltd (**ChemGenex**)

ACN/ARSN: 000 248 304

1. Details of substantial holder (1)

Name: Cephalon CXS Holdings Pty Ltd (**Cephalon CXS**)

ACN/ARSN (if applicable): 150 102 659

There was a change in the interests of the substantial holder on: 29 April 2011

The previous notice was given to the company on: 29 April 2011

The previous notice was dated: 29 April 2011

2. Previous and present voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

Class of securities (4)	Previous Notice		Present notice	
	Person's votes	Voting power (5)	Person's votes	Voting power (5)
Ordinary shares	138,025,831	44.05%	148,371,107	47.32%

3. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of Change	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Person's votes affected
See Annexure B	Cephalon CXS	Acquisition of relevant interests under section 608(8) of the Corporations Act as a result of acceptances of the share offer contained in Cephalon CXS's bidder's statement dated 13 April 2011 (Acceptances).	\$0.70 per ordinary share	See Annexure B	See Annexure B
See Annexure B	Cephalon International Holdings, Inc. and Cephalon, Inc.	Acquisition of relevant interests under section 608(3)(b) of the Corporations Act as a result of the Acceptances.	Not applicable	See Annexure B	See Annexure B
See Annexure B	The related bodies corporate of Cephalon, Inc. listed in Annexure A.	Acquisition of relevant interests under section 608(3)(a) of the Corporations Act as a result of the Acceptances.	Not applicable	See Annexure B	See Annexure B

4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Nature of relevant interest (6)	Class and number of securities	Person's votes
Cephalon CXS	Cephalon International Holdings, Inc.	Cephalon International Holdings, Inc.	Relevant interest under section 608(3)(a) of the Corporations Act.	86,386,425 ordinary shares	86,386,425
	Accepting ChemGenex shareholders	Cephalon CXS	Relevant interest under section 608(8) of the Corporations Act	61,984,682 ordinary shares	61,984,682
Cephalon International Holdings, Inc.	Cephalon International Holdings, Inc.	Cephalon International Holdings, Inc.	Relevant interest under section 608(1)(a) of the Corporations Act.	86,386,425 ordinary shares	86,386,425
	Accepting ChemGenex shareholders	Cephalon CXS	Relevant interest under section 608(3)(b) of the Corporations Act	61,984,682 ordinary shares	61,984,682
Cephalon, Inc.	Cephalon International Holdings, Inc.	Cephalon International Holdings, Inc.	Relevant interest under section 608(3)(b) of the Corporations Act	86,386,425 ordinary shares	86,386,425
	Accepting ChemGenex shareholders	Cephalon CXS	Relevant interest under section 608(3)(b) of the Corporations Act.	61,984,682 ordinary shares	61,984,682
The related bodies corporate of Cephalon, Inc. listed in Annexure A.	Cephalon International Holdings, Inc.	Cephalon International Holdings, Inc.	Relevant interest under section 608(3)(a) of the Corporations Act.	86,386,425 ordinary shares	86,386,425
	Accepting ChemGenex shareholders	Cephalon CXS	Relevant interest under section 608(3)(a) of the Corporations Act.	61,984,682 ordinary shares	61,984,682

5. Changes in association

The persons who have become associates of, ceased to be associates (2) of, or have changed the nature of their association with (9), the substantial holder in relation to voting interests in the company or scheme are as follows:


Name and ACN/ARSN (if applicable)	Nature of association
Not applicable	Not applicable

6. Addresses


The addresses of persons named in this form are as follows:

Name	Address
Cephalon CXS	Level 2 37-39 Epping Road Macquarie Park NSW 2113
Cephalon International Holdings, Inc., Cephalon, Inc. and the related bodies corporate of Cephalon, Inc. listed in Annexure A	41 Moores Road Frazer PA 19355 United States of America

Signature

print name J. Kevin Buchi by his attorney Timothy Bowley capacity Under power of attorney
 sign here  date 2 May 2011

This is Annexure A of 1 page referred to in the Form 604 (Notice of change of interests of substantial holder) signed by me and dated 2 May 2011.


.....
J. Kevin Buchi by his attorney Timothy Bowley

ANNEXURE A

Anesta LLC
Anesta AG
Arana Therapeutics, Inc.
BioAssets Development Corporation
Biotan AG
Cephalon Australia Pty Ltd ACN 002 951 877
Cephalon Australia (Vic) Pty Ltd ACN 097 483 068
Cephalon (Bermuda) Limited
Cephalon Borinquen, Inc.
Cephalon B.V.
Cephalon Development Corporation
Cephalon France SAS
Cephalon Europe SAS
Cephalon GmbH
Cephalon Holdings Limited
Cephalon Investments, Inc.
Cephalon Italia S.r.L
Cephalon Limited
Cephalon Luxembourg S.a.r.l
Cephalon Management Company LLC
Cephalon Management Company LUX SCS
Cephalon Pharma ApS
Cephalon Pharma (Ireland) Limited
Cephalon Pharma SL
Cephalon Sp.z.o.o.
Cephalon Technologies Partners, Inc.
Cephalon Titrisation
Cephalon (UK) Limited
Cephalon Ventures Puerto Rico, Inc.
CIMA LABS INC.
East End Insurance Ltd.
Galenis-Promoção e Comercialização de Products Farmacêuticos LDA
Mepha GmbH
MEPHA-Investigação, Desenvolvimento e Fabricação Farmacêutica LDA
Mepha (Latino-Americana) S.A.
Mepha Pharma AG
Mepha Pharma GMBH
Mepha Pharma India Private Limited
Polarx Biopharmaceuticals, Inc.
Promics Pty Ltd ACN 089 138 063
SIA Mepha Baltics
Societe Civile Immobiliere Martigny

ANNEXURE B

This is the Annexure B of one page referred to in Form 604 (Notice of change of interests of substantial holder) signed by me and dated 2 May 2011.

print name J. Kevin Buchi by his attorney Timothy Bowley Capacity Under power of attorney

sign here  Date 2 May 2011

Details of changes in relevant interests pursuant to Acceptances:

Date of change	Class and number of securities affected	Person's votes affected
29 April 2011	10,345,276 ordinary shares	10,345,276